UNH Shorts Finally Cover as Peers Stay Under Pressure

UnitedHealth Group stands out this week not because of what the short book is doing, but because of what it just did: after 18 sessions frozen at 15.95 million shares, shorts cut their position by 12% in a single step.

Among the managed-care peer group, the short-covering in UNH is the clear outlier. CVS fell 3.8% on the week and ELV dropped 4.2%, while MOH lost more than 9%. UNH slipped just 2.1%, holding up better than the median peer move of roughly 2.9%. Short interest in UNH has now dropped to 14.0 million shares, equal to 1.55% of the free float, down from 15.95 million where it had been pinned since early October. That is a meaningful reduction after weeks of inertia, and it brings the short book back toward levels last seen before the pre-earnings build. With borrow availability effectively unlimited and the cost to borrow running at just 0.33%, there was no mechanical pressure forcing the cover. It was a decision.

The broader positioning picture remains relaxed rather than charged. Options lean slightly to the bullish side of neutral: the put/call ratio is at 0.80, about one standard deviation below its 20-day average of 0.82, continuing the drift away from the more defensive setup seen in mid-September when the ratio was running near 0.94. The ORTEX short score has edged down from 32.0 to 31.0 over the past week, a low reading that places UNH in a relatively uncrowded part of the short-interest spectrum. Nothing in the lending market or the options strip is flashing distress.

The analyst community is broadly constructive but showing some internal disagreement on valuation. Morgan Stanley raised its target to $531 on the day of this writing, maintaining Overweight. Wells Fargo moved the opposite direction, trimming to $487 while also keeping Overweight, a sign that the Q3 beat and the raised guidance have not yet fully closed the gap between the stock at $410 and what the Street thinks it is worth. The mean target across the analyst consensus sits at $477, implying roughly 16% upside from current levels. Valuation multiples have drifted higher over the past month: the trailing P/E has expanded by about 0.7 turns to 18.0x, and the price-to-book has risen to 3.4x. The EPS momentum score ranks in the 84th percentile on a 30-day basis, reflecting the sharp upward revision to the full-year guidance of at least $20.50 after the Q3 beat of $4.69 adjusted EPS. The bear case centres on Medicare Advantage utilization pressure, the v28 risk-model changes still phasing in, and DOJ scrutiny that has not fully left the headlines.

One data point worth noting on the attention side: Wikipedia views for UNH are running at a z-score of 2.0 against the company's own 90-day history, the highest retail-attention reading available in this snapshot. That spike followed the Q3 print and the subsequent rally, and it tracks with the options and short-interest moves: the stock has drawn enough interest that the pre-earnings short book could no longer sit still.

The next scheduled earnings event is January 12. Between now and then, the level to watch is whether short interest continues to unwind from the 14.0 million share resting point, or rebuilds as the debate over 2027 Medicare Advantage rates and Medicaid trends sharpens into year-end.